Tags : Metastatic Breast Cancer

Novartis Reports the Reimbursement of Kisqali as 1L Treatment for

Shots: The reimbursement of Kisqali is a testament to the ongoing need for public access to the treatment. The Canadian Province, Quebec will reimburse Kisqali + Letrozole under the public drug program as 1L treatment for HR+, HER2-negative advanced or metastatic breast cancer in post-menopausal women Novartis will collaborate with remaining province and territories in […]Read More

Pfizer’s Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated

Shots: The approval is based on P-III EMBRACA study results assessing Talzenna (qd, 1mg) vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) in 431 patients in ratio (2:1) with inherited BRCA1/2 mutation & LA or m-triple-negative or HR+/HER2- breast cancer, prior treated with 3L CT regimen The P-III EMBRACA study results: mPFS (8.6 mos.vs 5.6mos.); ORR (62.6% vs 27.2%); 46% […]Read More

Celltrion’s Herzuma (Trastuzumab Biosimilar, CT-P6) Receives EMA Approval for Breast

Shots: The approval is based on positive opinion by CHMP (EMA) assessing Herzuma and reference trastuzumab in patients with HER2 overexpression/gene amplification tumors in breast cancer, metastatic breast cancer and metastatic gastric cancer The study resulted in a non-inferiority data demonstrating efficacy, safety, immunogenicity, PD and PK in patients Herzuma (trastuzumab biosimilar, CT-P6) is a […]Read More